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The usefulness of diet containing Telfairia occidentalis seeds, in managing benign prostatic hyperplasia (BPH) in 
rats was studied. Twenty male Wistar rats were divided into four equal groups. BPH was induced by sub-cutaneous injection 
of dihydrotestosterone (DHT) and estradiol valerate (ratio, 10:1) every other day for 28 days. Rats in the test group were 
placed on the test diet for 7 days following disease induction. One control group (DC) was fed on a normal diet for 7 days 
following disease induction. Two other control groups, HC and HDC, were given sub-cutaneous olive oil (vehicle) for the 
same duration, and placed on the test diet and normal diet, respectively. Markers of BPH, and hormone profile were 
determined using standard methods. The results show that relative prostate weight and protein content of the prostates were 
lower [albeit not significantly (p>0.05)] in the test group, relative to the DC group. Serum prostatic acid phosphatase 
concentrations (U/L) decreased significantly (p<0.05) from 2.9 ± 0.2 in the DC group to 2.1 ± 0.7 in the test group. 
Histological findings corroborate these data. The testosterone: estradiol ratio (×103) was increased from 4.0 ± 0.2 in the DC 
group to 4.6 ± 0.2 in the test group. The test diet reduced the mass and secretory activity of the enlarged prostate and may act 
by increasing the testosterone: estradiol ratio. 
 






Benign prostatic hyperplasia (BPH) is an age-related non-malignant enlargement of the prostate gland that results 
from a neoplastic unregulated growth of the prostate gland (Paglone, 2010). Its etiology is still largely unresolved. However, 
it seems that the patho-etiologic mechanism is endocrine controlled and involves alterations in the metabolism of androgens 
and estrogens (Suzuki et al., 1995). Some studies have however linked the metabolic syndrome to the etiology of BPH (Ejike 
and Ezeanyika, 2008). 
Treatment options for BPH target either a reduction in the mass of the prostate gland (static component of BPH) or 
a relaxation of the prostatic muscle tone (dynamic component of BPH). They include watchful waiting, medical therapy with 
α-blockers or 5 α-reductase inhibitors, hormone therapy, surgery and phytotherapy (Watson et al., 2004; Kaplan, 2006). The 
use of complementary and alternative medicine (CAM) for the treatment of BPH is becoming popular. It is estimated that 
30% of men diagnosed with prostate disease in North America use some CAM products (Nickel et al., 2008), while such 
products constitute approximately 50% of all medicines prescribed for BPH in Italy (Di Silverio et al., 1993) and almost 60% 
of such prescriptions in Germany and Austria (Buck, 1996). 
This study investigated the usefulness of the seeds of fluted pumpkin (Telfairia occidentalis Hook f.) – a creeping 
tropical vine, belonging to the family Curcurbitaceae – as a principal agent in a food-based therapy for the management of the 
static component of experimental (hormone-induced) BPH in Wistar rats. The results will contribute to the search for locally 





Materials and Methods 
Diet Formulation 
 
Mature fluted pumpkin seeds were purchased from a local market in Nigeria. The fruits were sliced open and the 
seeds harvested, cleaned and shelled manually. Good seeds were carefully selected and boiled for 1 hour in tap water. The 
boiled seeds were thereafter dried in an oven at 40°C to a constant weight, and then milled in a laboratory mill. A diet 
containing 15% of the boiled, oven-dried and milled seeds and 75% normal rat chow was prepared, homogenized thoroughly 
and pelletized manually. The pellets were dried to a constant weight in an oven at 40°C and thereafter cooled and stored in 
air-tight containers until used as test diet. Normal manually-pelletized and oven-dried rat chow was used as control diets in 
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Rats 
 
Twenty 4-week old male Wistar rats weighing approximately 111 g each were obtained from the Animal Breeding 
Unit of the Faculty of Veterinary Medicine, University of Nigeria, Nsukka. On arrival, the rats were acclimatized to the 
animal house for one week before being randomly assigned to four cages/groups. Housed in standard plastic cages (5 per 
cage), the rats were exposed to approximately 12 hour light/dark cycles under humid tropical conditions, and given tap water 




Table 1: Design of study 
Group Hormonal Treatment (sub-cutaneous injections) Diet 
(0-28th  day) 
Diet 
(29th-35th day) 
Test 9mg/kg body weight DHT + 0.9mg/kg body weight estradiol 
valerate every other day 




9mg/kg body weight. DHT + 0.9mg/kg body weight estradiol 








Olive oil (vehicle) every other day Normal Normal 
DHT and estradiol valerate were procured from Sigma-Aldrich Laboratories GmbH, Germany and Schering AG, Berlin, 
Germany, respectively. TO stands for Telfairia occidentalis seeds. 
 
After 35 days, the rats were fasted for 12 hours, anaesthetized by a brief exposure to trichloromethane vapor, and 
bled exhaustively by cardiac puncture. The sera were carefully separated and used for the biochemical analyses. Each rat’s 
carcass was promptly dissected and the prostates were carefully excised. Two prostates per group were randomly selected 
and their dorso-lateral lobes were dissected out and immediately processed for histology. The other three prostates per group 
were freed of external fascias, washed in cold normal saline, blotted with filter paper, and weighed on a sensitive balance. 
Subsequently, they were homogenized in ice-cold normal saline and the homogenates used for the determination of the 
protein content of the prostates. 
 
Assays and Determinations 
Prostatic Acid Phosphatase (PAP) Assay 
 
PAP levels in serum were measured using the method of Fishman and Lerhner (1953). The assay is based on the 
hydrolysis of p-nitrophenyl phosphate by acid phosphatases present in serum, in an acid pH medium, to give p-nitrophenol. 
Since tartaric acid is an inhibitor of acid phosphatases of prostatic origin, the tartarate-sensitive fraction of the acid 
phosphatases in serum (PAP) is measured by the difference in activity observed when the assay is carried out in the absence 
and presence of tartaric acid. 
 
Determination of Serum Prolactin, Testosterone and Estradiol Concentrations 
 
A solid phase enzyme immunoassay (EIA) quantitative method was employed for the determination of the 
concentration of each hormone in the serum. The prolactin protocol utilizes 2 antibodies directed against distinct antigenic 
determinants of the prolactin molecule as described by Babiel et al., (1990). The testosterone protocol is based on the method 
of Turkes et al., (1979) and involves the competition of testosterone in serum and enzyme-labeled testosterone for binding 
with anti-testosterone antibody immobilized on the microwell surface. The estradiol protocol also utilizes the competitive 
binding principle as described by Bouve et al., (1992). 
 
Determination of Protein Content of the Prostate 
 
A 200 mg portion of prostate tissue was homogenized in 10 ml of normal saline. An aliquot (0.02 ml) of the 
homogenate was used to determine the protein content using the Biuret method as described by Layne (1957). The method is 
based on the principle that proteins form a stable violet-colored complex with copper II ions at alkaline pH. The depth of the 
color is a measure of the number of peptide bonds present in the sample. The protein content of the prostate was determined 
by multiplying the amount of protein per aliquot by the dilution factor, and thereafter adjusting for the total volume of tissue 




The dorso-lateral lobes of the prostates were fixed in Bouin’s fixative for 24 h. They were then dehydrated in 
grades of ethanol, cleared in xylene, then infiltrated with, and embedded in paraffin. Each was sectioned at 5 μm and stained 
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Data Analysis 
 
Descriptive statistics was done and the results presented as means ± standard deviations. Differences between 
means were separated by One-Way ANOVA, followed by post hoc multiple comparisons, with the least significant threshold 
employed at p ≤ 0.05. 
 
Table 2: Markers of prostatic hyperplasia in rats in the test and control groups 
 TEST DC HC HDC 
Prostate Wt (g) 0.55 ± 0.14 0.60 ± 0.04 0.50 ± 0.07 0.50 ± 0.07 
P  0.321 0.158 0.158 
Rel. Prostate Wt (×1000) 2.8 ± 0.8 3.0 ± 0.9 2.5 ± 0.8 2.4 ± 0.9 
P  0.750 0.048 0.041 
Prostate Wt/Testes Wt 0.88 ± 0.18 1.13 ± 0.18 0.23 ± 0.03 0.23 ± 0.06 
P  0.125 0.007 0.008 
Protein Content (mg/tissue) 60.0 ± 3.3 65.2 ± 1.9 33.3 ± 2.0 35.7 ± 0.8 
P  0.074 <0.001 <0.001 
PAP (U/L) 2.1 ± 0.7 2.9 ± 0.2 1.6 ± 0.4 1.8 ± 0.5 
P  0.038 0.135 0.333 
PAP/Prostate Wt (U/L/g) 5.4 ± 1.0 5.6 ± 0.6 3.2 ± 1.2 3.7 ± 0.5 
P  0.776 0.066 0.129 
P values are for comparisons between the test group and the different control groups 
 
Table 3: Hormonal profile of rats in the test and control groups 
 TEST DC HC HDC 
Prolactin (ng/ml) 6.4 ± 0.1 5.6 ± 0.4 5.7 ± 0.7 5.6 ± 0.7 
P  0.073 0.112 0.087 
Estradiol (ng/ml) 883.1 ± 11.0 902.4 ± 5.6 796.1 ± 73.2 692.5 ± 22.3 
P  0.558 0.025 <0.001 
Testosterone (ng/ml) 4.1 ± 0.2 3.6 ± 0.2 12.0 ± 0.6 12.9 ± 0.2 
P  0.163 <0.001 <0.001 
Testosterone/Estradiol (×1000) 4.6 ± 0.2 4.0 ± 0.2 15.2 ± 1.7 20.6 ± 0.7 
P  0.463 <0.01 <0.01 







The mean wet weight of the prostates was highest in the DC group and lowest in the HC and HDC groups. 
However, there was no statistically significant (p>0.05) difference between the mean weight of the prostates of rats in the test 
group and those in any of the three control groups. Mean relative prostate weights were significantly (p<0.05) lower in the 
HC and HDC groups, relative to the test group. The value for the test group, though less than that of the DC group, was 
statistically similar (p>0.05) to it. The prostate weight relative to testes weight values followed a pattern that is similar to that 
of the relative prostate weight. The mean protein content of the rats’ prostates was highest in the DC group and lowest in the 
HC group. The value for the test group was not significantly (p>0.05) different from that of the DC group, though it was 
clearly smaller. 
Akin to protein content of the prostates, mean serum PAP was highest in the DC group and lowest in the HC group. 
The mean PAP values of the DC group was significantly (p<0.05) higher than that of the test group which was statistically 
comparable (p>0.05) to those of the HC and HDC groups. Mean PAP relative to prostate weight values were not significantly 
(p>0.05) different between the test group and any of the three control groups. 
Figures 1 and 2 show extensive branching of the glandular ducts and the massive columnar epithelial in-folding 
lining the ducts.  A decrease in the branching of the glandular ducts and epithelial convolutions in the test group (Fig. 1) 
relative to the DC group (Fig. 2) is seen. Also seen are the secretions in the lumens (Figs 1 and 2). Figures 3 and 4 show that 
glandular duct branching is not extensive, and the absence of in-folding of the epithelial cells in the HC group (Fig. 3) and the 
HDC group (Fig. 4). Epithelial cells in the HC group appear small and disjointed while those in the HDC appear more closely 
packed and bigger in size. Luminal secretions are also seen in both figures. 
The mean concentrations of prolactin in the sera of the rats were statistically similar (p>0.05) between the test 
group and each of the controls. Mean serum estradiol concentrations were significantly (p<0.05) lower in the HC and HDC 
groups relative to the test group. However, the test group had values that were not significantly (p>0.05) different from that 
of the DC group. Conversely, mean serum testosterone values were significantly (p<0.05) higher in the DC and HDC groups, 
relative to the test group which had (insignificantly) higher mean values compared to the DC group. The testosterone to 
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Discussion 
 
A recent study had shown that the seeds of T. occidentalis when incorporated into the diets of rats, supported 
growth and maintenance of body weight, and showed no signs of toxicity (Ejike et al., 2010a). However, beyond a 15% level 
of dietary incorporation of the seeds, significant hyperglycemia resulted (Ejike et al., 2010b). Since it was important to 
incorporate a quantity of the seeds large enough to have a therapeutic effect, without resulting in metabolic derangements, the 
15% dietary incorporation was chosen for this study.  
Eunuchs or hypogonadal individuals, and men who were castrated prior to puberty are known not to suffer from 
BPH. Also, in the rare disorders of androgen resistance like testicular feminization and 5 α-reductase deficiency, only a 
remnant prostate is present (Wilson and Roehrborn, 1999). For these reasons, intact rats were chosen for this study such that 
proper comparison with BPH in men could be made. 
The test diet clearly reduced both the mean prostate weight and mean relative weights of the prostates of rats in the 
test group, relative to the DC group, though not (statistically) significantly so. The mean relative weights of the prostates of 
the groups that did not receive the exogenous hormones were only marginally significantly lower than values got for the test 
group. Again, the test diet also resulted in a reduction in the mean ratio of prostate weight to testes weight of the test group, 
relative to the DC group. In the same vein, the mean protein content of the rat prostates was lower in the test group, compared 
to the DC group, though the difference was not statistically significant. 
Increase in cell number (hyperplasia) of the prostate would rationally come with a collateral increase in its weight 
(especially its relative weight, since it corrects for differences in whole body weight). It should also come with an increased 
prostate weight to testes weight ratio, since testosterone (produced by the Leydig cells of the testes) affects the growth of the 
prostate and organ mass is often related to secretory activity. Furthermore, increase in cell number in a tissue also goes with a 
collateral increase in the protein content of the tissue, and for the prostate, occurs only when DHT is 12-17% of the normal 
physiological values (Wright et al., 1999). Though the test diets reduced the increase in cell number in the prostates of rats in 
the test group (as assessed by the measured parameters) relative to the DC group, the differences between the means of both 
groups were not statistically significant. However, it is note-worthy that any reduction in the mass of the prostate would 
translate to a reduction in the irritative symptoms of BPH which are usually the most bothersome symptoms (Barry, 2001). 
Symptom severity in BPH is known to correlate with overall health status (Eaton, 2003) such that any agent that can reduce 
the symptoms of BPH (in this case by reducing the mass of the prostate), no matter how slightly it does it, is usually useful. 
The test diet therefore could be useful in the management of BPH. 
Testosterone (in a dose-dependent fashion) is known to stimulate the secretory capacity of the prostate (Banerjee et 
al., 1998). PAP is one of the prostatic secretions used as a marker of prostatic diseases and as an indicator of treatment 
progress (Bauer, 1988). Elevations in PAP levels have been reported in animals treated with DHT and estradiol and may be 
due to increased lysosomal activity (Jeyaraj et al., 2000). The higher values obtained for PAP in the groups that received the 
hormones corroborate the increase in secretory activity (due to hyperplasia) especially in the DC group. The fact that the test 
diet resulted in the test group having a mean PAP value that is statistically similar to those of the HC and HDC groups 
buttresses its effectiveness in managing aberrant growth of the prostate. 
These data are supported by the decrease in the thickening of the epithelial cells and their convolutions as seen in 
the histological sections of rats in the test group, relative to the DC group. The fact that both the test group and the DC group 
had higher indices for the markers of hyperplasia assessed in this study, relative to the HC and HDC groups, clearly shows 
that hyperplasia was successfully induced. Also, the fact that all such assessed indices were lower in the test group, relative to 
the DC group shows that the test diet contains active ingredients that clearly reversed aberrant growth of prostate cells. The 
short duration of treatment with the test diet (one week), may have been the reason for the absence of a statistically 
significant reversal of hyperplasia in the test group as was the case in the study of the ability of the same test diet to inhibit 
the induction of hyperplasia (where the diet was fed alongside hormonal challenge for 28 days) (Ejike, 2010). However it was 
important not to exceed one week, as such an elongation of the time of treatment could generate false positive results as the 
prostates of rats in the test and DC groups would have naturally regressed as a result of the withdrawal of hormone treatment. 
Bearing in mind that hormonal induction of BPH in rats has been shown not to result in derangements in serum 
macromolecular metabolism (Ejike and Ezeanyika, 2010), the serum concentrations of prolactin, estradiol and testosterone 
were studied, in order to appreciate the possible mechanism(s) through which the test diet achieved the lowering of cell 
proliferation in the prostates of rats in the test group. 
Prolactin provides an additional growth regulatory mechanism for the prostate (Nevalainen et al., 1997) and its 
over-expression can result in prostatic enlargement (Wennbo et al., 1997). However, estradiol modulates the secretory 
activity of the pituitary, and thus may in turn moderate the level of prolactin in the system (Kaufman and Vermeulen, 2005). 
The exogenous estradiol administered to the rats in the test and DC groups may have ensured that their levels of prolactin 
remained statistically similar to those of the other groups, despite the induction of BPH. Prolactin may therefore not have 
been responsible for the induction or management of prostate cell proliferation observed in this study. 
Estrogen sufficiency typically results in a decrease in testosterone concentration in serum. This is because estrogens 
exert a negative feed back control on pituitary secretion (McPherson et al., 2001). Though mean testosterone levels were 
lower in the test and DC groups, relative to the HC and HDC groups, the test group however had higher mean values 
compared to the DC group. The low mean value for testosterone found in the DC group is not surprising, for reasons adduced 
above. It appears that the test diet resulted in a slight increase in the serum testosterone concentration of rats in the test group, 
relative to the DC group. 
Serum estradiol levels were expectedly higher in the test and DC groups, due to the supra-normal doses of estradiol 
valerate which they received. Jeyaraj et al. (2000) had reported a similar high level of estradiol in animals treated with DHT 
and estradiol, and concluded that the induction of hyperplastic changes in the prostate of the animals may be an estrogen 
related effect. The data from this study support this view, as it appears that the test diet reduced (albeit slightly) the serum 
concentrations of estradiol in rats in the test group, relative to the DC group. 
doi: 10.4314/ajtcam.v8i4.9








Figure 2: Histological section of prostate tissue from the DC group (Magnification: × 100) 
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BPH is associated with a reduced androgen: estrogen ratio (Suzuki et al., 1995). With a reduced androgen: estrogen 
ratio, epithelial cells secrete transforming growth factor beta (TGF-β), a pleitropic factor that induces smooth muscle 
differentiation and increases the extracellular matrix in the surrounding stromal cells (Zavidil and Bottinger, 2005), events 
that are typical of BPH. Interestingly, the test diet resulted in the testosterone to estradiol ratio of the test group being higher 
than that of the DC group (though significantly lower than those of the HC and HDC groups). Clearly, the test diet increased 
the androgen: estrogen ratio of the test group relative to the DC group, and possibly, through that mechanism reversed the 
hyperplasia induced by the administration of exogenous hormones. 
It is important to note that there are as much inter species differences as there are similarities in nature, such that 
these findings should be cautiously extrapolated to humans. A comparison of the T. occidentalis seeds incorporated diet and a 
standard drug or phytotherapeutic agent of proven efficiency in managing BPH is needed, while further studies to clearly 
elucidate the mechanism of action of the test diet are imperative. 
In conclusion, results from this study show that a diet incorporating 15% T. occidentalis seeds was useful in 
managing experimantal BPH in Wistar rats. It possibly achieves this by increasing the level of serum testosterone while 
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